Oramed Announces Successful Meeting with FDA for Oral Insulin

JERUSALEM, Sept. 5, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, […]

Categories: Press Releases|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, August 29, 2017 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 19th Annual Global Investment Conference, taking place on […]

Categories: Press Releases|Tags: |

Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs

JERUSALEM, July 18, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs.

“We are very pleased to welcome Dr. […]

Categories: Press Releases|Tags: |

Oramed to Present at BIT’S 5th World Congress of Diabetes on July 13, 2017

JERUSALEM, July 12, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed’s Chief Scientific Officer, will deliver a presentation titled, “Oral Insulin for Diabetes Treatment: […]

Categories: Press Releases|Tags: |

Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program

JERUSALEM, July 11, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to schedule an End-of-Phase II meeting with Oramed […]

Categories: Press Releases|Tags: |

Oramed Announces Dual-Listing on Tel Aviv Stock Exchange

JERUSALEM, July 5, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel Securities Authority to dual-list its common stock on the Tel […]

Categories: Press Releases|Tags: |

Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule

JERUSALEM, June 27, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, “Methods and […]

Categories: Press Releases|Tags: |

Oramed to Present at the American Diabetes Association 77th Scientific Sessions

JERUSALEM, June 6, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing the recent Phase IIb study of its orally ingestible insulin capsule, ORMD-0801, will be presented […]

Categories: Press Releases|Tags: |

Oramed to Present at Conferences Next Week

JERUSALEM, May 18, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that  Chief Executive Officer, Nadav Kidron, will present at three conferences next week in Tel Aviv, Israel.

Oppenheimer’s 17th Annual […]

Categories: Press Releases|Tags: |

Oramed Granted Canadian Patent for GLP-1 Analog Capsule

JERUSALEM, May 9, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, “Methods and Compositions for Oral Administration of […]

Categories: Press Releases|Tags: |